Embecta Corp. (EMBC) Stock

Embecta Corp. (EMBC) is a Healthcare stock trading at $5.47 (as of 2026-08-20), with a market capitalization of $309.93M and a trailing P/E of 3.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Embecta Corp. is a medical device company focused on products and tools for people managing diabetes, including pen needles, syringes, safety devices, and related digital applications. It distributes these offerings through wholesalers and distributors in the United States and internationally.

Understand Embecta Corp.: how it makes money

Embecta makes diabetes-related medical devices (including pen needles, syringes, and safety devices) and digital tools that help people manage diabetes, and it primarily sells these products to wholesalers and distributors in the United States and internationally.

The company’s profit model is tied to selling diabetes-focused medical devices through wholesale and distributor channels, and it reports that 100% of revenue flows through company systems.

Business quality (Weak): Product-specific revenue declines on an adjusted constant currency basis are a key near-term signal to watch, while the company’s reported 100% revenue flow through company systems supports operating control of its go-to-market.

Valuation: At 2× earnings, EMBC trades 95% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

Diabetes-focused portfolio across needles, syringes, safety devices, and digital applications: This breadth can support ongoing demand for diabetes management tools sold through wholesalers and distributors.
High reported profitability for the quarter: Gross margin was 57.6% and operating margin was 15.8% (for the period ended 2026-03-31).
Reported operating transparency into the revenue path: The company reports that 100% of revenue is flowing through company systems.

Bear case

Material declines reported in key product categories: Pen needle revenue declined by -20.4% and syringe revenue declined by -14.6% on an adjusted constant currency basis (and other categories also declined).
Contract manufacturing declines were steep: Contract Manufacturing Revenue Decline on an Adjusted Constant Currency Basis was -43.2%, which may indicate weak demand or unfavorable commercial conditions in that area.
Sales depend on wholesaler and distributor channels: Because the company primarily sells to wholesalers and distributors, changes in their ordering behavior can impact reported results.

Valuation — source: SEC EDGAR (first-party)
Price	$5.47
Market Cap	$309.93M
P/E Ratio	3.5
EV / EBITDA	5.8
Price / Sales	0.30
FCF Yield	53.1%
DCF Value (model)	$188.94
DCF Upside vs Price	3354.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.08B
Net Margin	8.8%
Revenue Growth (YoY)	-8.1%
EPS Growth (YoY)	-53.8%
FCF Growth (YoY)	-49.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	1.67 (distress)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	3.5
Sector P/E (Healthcare)	21.6
Industry P/E (Medical Equipment)	32.9
vs Sector	-83.6%
vs Industry	-89.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($81.04M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Devdatt Kurdikar
Employees	2,000
Country	US
IPO Date	2022-03-22

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.